<DOC>
	<DOCNO>NCT00819013</DOCNO>
	<brief_summary>This multi-center study conduct United States 80 healthy adult subject . Subjects schedule receive total two ( 2 ) injection 1 injection administer . Subjects randomize accord randomization scheme .</brief_summary>
	<brief_title>Safety Study Recombinant M2e Influenza-A Vaccine Healthy Adults</brief_title>
	<detailed_description>All subject follow 60 day post-randomization influenza season . Following influenza season , subset subject receive booster vaccine 12 month time point . The subject assess 2 day , 7 day , 15 day , 30 day 6 month follow booster vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult male females 18 40 year age good general health Known allergy severe reaction vaccine component include adjuvant History severe allergic reaction , include angioedema ; History asthma recurrent wheezing ; ( current within past 2 year ) ; History neurological symptom sign follow administration vaccine ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>